Four things to know:
1. Some members who have plans operated by Cigna Pharmacy saw Novartis’ Cosentyx (generic name secukinumab) moved to a higher-priced tier for non-preferred prescriptions, according to AJMC.
2. A dermatologist showed AJMC a letter indicating Cigna may start to offer members an incentive to switch from Cosentyx to Eli Lilly’s Taltz (generic name ixekizumab). Both drugs are used to treat psoriasis and psoriatic arthritis.
3. According to the letter, patients could receive the $500 debit card if they fill the first prescription before Aug. 31 and the second before Dec. 31.
4. In a statement to AJMC, Cigna said its members were “offered several alternative medications that are equally effective and more affordable. In rare occasions when a patient is not able to use the preferred option, we recommend that our clients offer an efficient review process to assist those patients in obtaining a non-formulary medication in these instances.”
Read more here.
More articles on payers:
BCBS of Minnesota CEO Dr. Craig Samitt to retire
10 for-profit insurers, ranked by share of Medicare Advantage
31 payer exec moves
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
